<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anticardiolipin antibodies are autoantibodies clinically associated with <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Systemic <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:mp ids='MP_0005048'>thrombosis</z:mp> of the vascular access for haemodialysis coexist with immunoregulation abnormalities in <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to analyse the incidence of thrombotic episodes and the presence of anticardiolipin antibodies and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> in 73 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>--51 on haemodialysis and 22 on conservative treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Four (18%) patients on conservative treatment had IgG-anticardiolipin, three of them also having <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Sixteen (31%) patients on haemodialysis showed IgG-anticardiolipin and 11 (22%) <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>; overall, 19 (37%) patients on haemodialysis had IgG-anticardiolipin and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This greater incidence in haemodialysis was associated with a more frequent use of cuprophane membranes (68% versus 34%, P less than 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>--one on conservative treatment--met criteria for the diagnosis of <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e>, clinically characterised by <z:mp ids='MP_0005048'>thrombosis</z:mp> of the vascular access </plain></SENT>
<SENT sid="7" pm="."><plain>IgG-anticardiolipin and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> are frequently found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> and their incidence increases with haemodialysis, probably due to some kind of membrane bioincompatibility </plain></SENT>
<SENT sid="8" pm="."><plain>IgG-anticardiolipin and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> can be associated with thrombotic episodes, being constituents of an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>-related <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>